TrialSignal
Clinical trial intelligence report
A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 19, 2026
NCT ID
NCT04232969
Status
COMPLETED
Phase
Phase 3
Sponsor
University College, London
Executive brief
Investment-Ready Snapshot
The Exenatide-PD3 trial represents a significant advancement in the exploration of exenatide as a potential disease-modifying treatment for Parkinson's disease, a market projected to grow substantially due to increasing prevalence and unmet medical needs. If successful, this trial could position exenatide as a first-in-class therapy for PD, enhancing its commercial value beyond its current indication for type 2 diabetes. The competitive landscape includes other neuroprotective agents in development, necessitating a thorough analysis of differentiation and potential market entry strategies. Diligence should focus on the trial's outcomes, regulatory pathways, and potential partnerships for commercialization.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04232969
Indication
Parkinson's Disease
Modality
small molecule
Target
Exenatide is a GLP-1 receptor agonist, which may exert neuroprotective effects by enhancing neuronal survival and function, potentially slowing the degeneration of dopaminergic neurons in Parkinson's disease.
Intervention
Exenatide extended release 2mg (Bydureon)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.